Bifosfonatos y osteonecrosis de los maxilares. Consideraciones sobre su tratamiento

Abstract

Bisphosphonates are strong osteoclastic inhibitor activities, being these drugs usually for treatment of multiple myeloma and bone metastases of solid tumors like breast cancer. The osteonecrosis of the maxillary bones was first described in 2003. The relation of these medicines and maxillary bone osteonecrosis still uncertain. The incidence of this bone necrosis was very low before biphosphonates using. Nowadays this complication reach at least 10% of patients in these therapy using. The present work mean to alert for possible complication in biphosphonates using patients, thru a literature review and a clinical case presentation.